Option Care Health, Inc. Q2 FY2025 earnings call

• Option Care Health delivered balanced growth across the portfolio in Q2 2025 and increased guidance for revenue, adjusted EBITDA, and adjusted EPS for the year.
• The company has thrived through various industry challenges over nearly 10 years and is well-positioned with a resilient operating model.
• Capitalized on shifting competitive dynamics, payer partnerships, and national scale with local responsiveness.
• Strong performance in acute, chronic, and rare/orphan therapies. Focused on relationships with health plans and pharma partners.
• Strong balance sheet and cash flow generation, with $90 million in cash flow from operations in Q2 and over $320 million expected for the full year.
• Investments in AI, advanced analytics, Palantir, and the advanced practitioner model to drive growth and efficiency.

Revenue grew 15.4% in the second quarter with balanced performance across the portfolio. Acute therapy and chronic therapies both saw mid-teens growth. Rare and orphan therapies also performed well. Gross profit was $269 million, up almost 8% year-over-year. Adjusted EBITDA was $114 million, up 5.2% year-over-year, representing 8.1% of net revenue. Adjusted earnings per share were $0.41, up 10.8% year-over-year.

• Full-year 2025 revenue expected to be $5.5 billion to $5.65 billion.
• Adjusted EBITDA guidance increased to $465 million to $475 million.
• Adjusted EPS guidance increased to $1.65 to $1.72.
• Expect to generate over $320 million in cash flow from operations for the full year.

• Potential impact of tariffs, MFN pricing, and similar policy changes, but guidance assumes no material financial impact in 2025.
• Uncertainty around the implementation and effect of MFN pricing on the business.

Q: Can you talk about conversations with payers regarding site of service redirection?

A: John Rademacher mentioned productive conversations, with heightened interest in site of care initiatives and volumes picking up in areas where payers are looking for alternatives to higher cost settings.

Q: Update on Stelara expectations for the year?

A: Michael Shapiro said the negative impact in Q2 was ~$20 million, and full-year impact is in the higher end of the $60M-$70M range, which is fully contemplated in guidance.

Q: Market share on acute and chronic sides?

A: Michael Shapiro discussed acute therapy growth in a mature category with mid-teens growth, and chronic therapies growing in low double digits.

Q: OpEx growth and MFN exposure?

A: Michael Shapiro said SG&A growth is due to acquisitions and growth initiatives, and MFN impact is too early to tell with no material impact expected in 2025.